If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for six months following the last dose of study drug
Males and females with reproductive potential must agree to use two forms of medically approved contraceptive precautions and for at least  months following the last dose of biochemoradiation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Parts A and B: If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for six months following the last dose of study drug
Parts C, D and E: If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug
Male and female participants of reproductive potential must agree to use medically approved contraceptive precautions during the trial and  to  months (as appropriate) following last dose of study drug.
Females of child-bearing potential and males must agree to use highly effective contraceptive precautions during the trial and up to  months following the last dose of study drug.
Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for  months following the last dose of study drug
Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for  months following the last dose of study drug
Males and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for at least  months following the last dose of study drug. Females with childbearing potential must have had a negative serum pregnancy test  days before the first dose of study drug and must not be breast-feeding.
If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for  months following the last dose of study drug. If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within  days of the first dose of study drug and must not be breastfeeding.
If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug.
Males and females with reproductive potential must agree to use medically approved contraceptive precautions starting  weeks prior to initiation of the therapy and during the trial and for  months following the last dose of study drug
Males and females (reproductive potential): Use medically approved contraceptive precautions during the study and for  months following the last dose of study drug.
Males and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for  months following the last dose of any study drug.
